(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
6 U.S. States for Climbing - 2Figure out How to Streamline Eco-friendliness in Your Volvo XC40
- 3Sought-After Extravagance Ocean side Objections for a Lovely Escape
- 4Watching ‘Home Alone’ with the kids this holiday season? Brace yourself for '6-7.'
- 5Getting Your Youngsters' Future: Grasping Legacy Regulations
- Israel faces tough choices over haredi draft exemptions, legal expert warns
- Best bar-b-que Style: Which One Is Your Number one?
- Exploring the Mind boggling Universe of Connections: Individual Bits of knowledge
- Extraordinary Shows to Long distance race on a Plane
- Instructions to Shield Your Gold Speculation from Possible Dangers: Fundamental Protections
- The most effective method to Move toward Compensation Conversations for Cutting edge Practice Enrolled Attendants
- Vote In favor of Your Favored Language Learning Applications
- 'We were genuinely astonished': This moss survived 9 months outside the International Space Station and could still grow on Earth
- Most loved VR Game for Wellness: Which Keeps You Dynamic?
